pipette
ESEspañol

The kinase inhibitor dabrafenib halts progression of cerebral cavernous malformations in a BRAF-independent manner

Maximiliano Arce, Hua Huang, Charlotte Rorsman, Iza Erzar, Joppe Oldenburg, Ying Sun, Ross Smith, Favour Chinyere Onyeogaziri, Stefano Barbera, Frida C Ahlstrand, Petter Ranefall, Anna H. Klemm, Mark Richards, Anna Dimberg, Lena Claesson, Peetra Ulrica Magnusson

Peer-reviewed journalReal-world use

In the authors' words

This journal does not let us republish the full abstract. Here are the two sentences Pipette selected, quoted from it. Read the rest at the publisher.

Main result
In conclusion, dabrafenib is a low–molecular weight compound that inhibits cavernoma pathogenesis, suggesting that CCMs could be treated with dabrafenib to block cavernoma growth and vascular leakage.

Appeared: Friday, October 23. Science Translational Medicine. Peer-reviewed journal.

DOI: 10.1126/scitranslmed.adr0448